Literature DB >> 25066389

Therapeutic potential and pharmacological activities of Atractylodes lancea (Thunb.) DC.

Nut Koonrungsesomboon1, Kesara Na-Bangchang2, Juntra Karbwang3.   

Abstract

The rhizome of Atractylodes lancea (A. lancea) (Thunb.) DC. (AL) is extensively used in Chinese, Thai, and Japanese traditional medicines as crude extracts/decoctions or a component in various herbal formulations. Various pharmacological activities of AL and its major constituents have been demonstrated in vitro, ex vivo, and in animal models. Results from the toxicity studies in animal models suggest safety profile of AL and its active constituents. Despite extensive use with positive impression in many diseases, there has not been a clinical study that can conclusively support its efficacy and safety profile in human. This review comprehensively summarizes current information on the pharmacological activities of AL and their active constituents including anticancer, anti-inflammatory, antimicrobial and antipyretic activities, as well as activities on central nervous, cardiovascular, and gastrointestinal systems.
Copyright © 2014 Hainan Medical College. Published by Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Atractylodes lancea; Herb; Pharmacological activities; Traditional medicine

Mesh:

Substances:

Year:  2014        PMID: 25066389     DOI: 10.1016/S1995-7645(14)60069-9

Source DB:  PubMed          Journal:  Asian Pac J Trop Med        ISSN: 1995-7645            Impact factor:   1.226


  22 in total

1.  Atractylon inhibits the tumorigenesis of glioblastoma through SIRT3 signaling.

Authors:  Shanshan Sun; Jiali Shi; Xin Wang; Changgang Huang; Yuqian Huang; Jiayun Xu; Yuanyuan Jiang; Liying Cao; Tian Xie; Yongjie Wang; Zhihui Huang
Journal:  Am J Cancer Res       Date:  2022-05-15       Impact factor: 5.942

2.  Properties of the Novel Chinese Herbal Medicine Formula Qu Du Qiang Fei I Hao Fang Warrant Further Research to Determine Its Clinical Efficacy in COVID-19 Treatment.

Authors:  Jennifer Cruz; Jason Trombley; Linda Carrington; Xiaodong Cheng
Journal:  Med Acupunct       Date:  2021-02-16

3.  Development and application of DNA markers to detect adulteration with Scopolia japonica in the medicinal herb Atractylodes lancea.

Authors:  Su Hong Oh; Yea Dam Kim; Cheol Seong Jang
Journal:  Food Sci Biotechnol       Date:  2021-11-26       Impact factor: 2.391

4.  Antiviral activities of atractylon from Atractylodis Rhizoma.

Authors:  Yang Cheng; Jing-Yin Mai; Tian-Lu Hou; Jian Ping; Jian-Jie Chen
Journal:  Mol Med Rep       Date:  2016-09-05       Impact factor: 2.952

5.  A novel exopolysaccharide elicitor from endophytic fungus Gilmaniella sp. AL12 on volatile oils accumulation in Atractylodes lancea.

Authors:  Fei Chen; Cheng-Gang Ren; Tong Zhou; Yu-Jia Wei; Chuan-Chao Dai
Journal:  Sci Rep       Date:  2016-10-05       Impact factor: 4.379

Review 6.  Pharmacological effects of medicinal components of Atractylodes lancea (Thunb.) DC.

Authors:  Xie Jun; Peng Fu; Yu Lei; Peng Cheng
Journal:  Chin Med       Date:  2018-11-27       Impact factor: 5.455

7.  Genetic and environmental factors influencing the contents of essential oil compounds in Atractylodes lancea.

Authors:  Takahiro Tsusaka; Bunsho Makino; Ryo Ohsawa; Hiroshi Ezura
Journal:  PLoS One       Date:  2019-05-28       Impact factor: 3.240

8.  Differential Gene Expression between Leaf and Rhizome in Atractylodes lancea: A Comparative Transcriptome Analysis.

Authors:  Qianqian Huang; Xiao Huang; Juan Deng; Hegang Liu; Yanwen Liu; Kun Yu; Bisheng Huang
Journal:  Front Plant Sci       Date:  2016-03-30       Impact factor: 5.753

Review 9.  Synergistic Effect and Molecular Mechanisms of Traditional Chinese Medicine on Regulating Tumor Microenvironment and Cancer Cells.

Authors:  Jingnan Xu; Zhuo Song; Qiujun Guo; Jie Li
Journal:  Biomed Res Int       Date:  2016-03-02       Impact factor: 3.411

Review 10.  Research and Development of Atractylodes lancea (Thunb) DC. as a Promising Candidate for Cholangiocarcinoma Chemotherapeutics.

Authors:  Kesara Na-Bangchang; Tullayakorn Plengsuriyakarn; Juntra Karbwang
Journal:  Evid Based Complement Alternat Med       Date:  2017-11-14       Impact factor: 2.629

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.